Monte Rosa Therapeutics (GLUE) Equity Average (2020 - 2026)

Monte Rosa Therapeutics' Equity Average history runs 7 years deep, the most recent figure standing at $377.5 million for Q1 2026.

• In Q1 2026, Equity Average rose 51.57% year-over-year to $377.5 million; the TTM figure through Mar 2026 stood at $377.5 million (up 51.57% YoY), while the FY2025 annual figure was $228.0 million, up 13.38% from the prior year.
• Equity Average was $377.5 million for Q1 2026 at Monte Rosa Therapeutics, up from $239.4 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $377.5 million in Q1 2026 to a low of $165.9 million in Q1 2024.
• Historically, Equity Average has averaged $251.4 million across 5 years, with a median of $249.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Equity Average jumped 715.85% in 2022, then plunged 35.6% in 2024.
• A 5-year view of Equity Average shows it stood at $281.3 million in 2022, then slumped by 35.33% to $181.9 million in 2023, then rose by 17.76% to $214.2 million in 2024, then increased by 11.79% to $239.4 million in 2025, then jumped by 57.65% to $377.5 million in 2026.
• The last three Equity Average figures came in at $377.5 million (Q1 2026), $239.4 million (Q4 2025), and $257.0 million (Q3 2025), per Business Quant data.